Asthma control and clinical remission in severe eosinophilic asthma (SEA) after 2 years of benralizumab treatment: prospective real-world data from XALOC-2

<bold>Background:</bold> Prospective long-term real-world data on the effectiveness of benralizumab on asthma symptom control in patients (pts) with SEA are lacking. <bold>Aim:</bold> Examine real-world effectiveness of benralizumab over 112 weeks (Wks). <bold>Methods:</bold> XALOC-2 comprises prospective, real-world studies of pts with SEA treated with benralizumab in Belgium, Canada, Germany and Switzerland. This 112 Wk integrated analysis assessed Asthma Control Questionnaire (ACQ) scores, annualised asthma exacerbation rate (AAER) and 3-component clinical remission (no exacerbations, no maintenance oral corticosteroid use, asthma symptom control [ACQ<1.5]). <bold>Results:</bold> Of 534 pts (median age 58 years; 49% female), median (IQR) ACQ score at baseline was 3.0 (2.2–3.8), decreasing to 1.2 (0.6–2.3; Wk 56) and remaining stable at 1.2 (0.5–2.2) to Wk 112 (Fig 1). Clinically meaningful improvements (minimal clinically-important difference threshold≥‒0.5) occurred in 58% of pts at Wk 1, increasing to 79% at Wk 112. AAER decreased by 85% from baseline to Wk 112. Overall, 1% met remission criteria at baseline vs 41% at Wk 112, with remission rates lower in pts with obesity than with normal BMI (42%/49%). <bold>Conclusion:</bold> Real-world patients with SEA showed early and sustained symptom control over 2 years of benralizumab treatment. More than 4 out of 10 patients were in remission after 2 years of treatment. <fig><object-id>erj;66/suppl_69/PA5705/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>